Novavax, Inc.
NVAX
$10.75
$0.676.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 147.14M | 70.45M | 239.24M | 666.66M | 88.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.14M | 70.45M | 239.24M | 666.66M | 88.31M |
| Cost of Revenue | 121.89M | 103.70M | 80.29M | 103.05M | 158.13M |
| Gross Profit | 25.25M | -33.26M | 158.95M | 563.60M | -69.82M |
| SG&A Expenses | -9.76M | 46.12M | 53.28M | 47.59M | 34.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.20M | 149.83M | 133.57M | 150.64M | 213.79M |
| Operating Income | 20.94M | -79.38M | 105.67M | 516.01M | -125.48M |
| Income Before Tax | 17.90M | -203.04M | 107.45M | 519.85M | -73.58M |
| Income Tax Expenses | 376.00K | -657.00K | 946.00K | 1.20M | 7.45M |
| Earnings from Continuing Operations | 17.53M | -202.38M | 106.51M | 518.65M | -81.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.53M | -202.38M | 106.51M | 518.65M | -81.03M |
| EBIT | 20.94M | -79.38M | 105.67M | 516.01M | -125.48M |
| EBITDA | 26.06M | -72.80M | 113.23M | 524.35M | -112.96M |
| EPS Basic | 0.11 | -1.25 | 0.66 | 3.22 | -0.51 |
| Normalized Basic EPS | 0.09 | -0.29 | 0.41 | 2.02 | -0.47 |
| EPS Diluted | 0.11 | -1.25 | 0.62 | 2.93 | -0.51 |
| Normalized Diluted EPS | 0.09 | -0.29 | 0.38 | 1.83 | -0.47 |
| Average Basic Shares Outstanding | 162.53M | 162.35M | 162.02M | 161.05M | 160.24M |
| Average Diluted Shares Outstanding | 165.18M | 162.35M | 177.22M | 177.63M | 160.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |